US20130171662A1 - Assay - Google Patents
Assay Download PDFInfo
- Publication number
- US20130171662A1 US20130171662A1 US13/512,823 US201013512823A US2013171662A1 US 20130171662 A1 US20130171662 A1 US 20130171662A1 US 201013512823 A US201013512823 A US 201013512823A US 2013171662 A1 US2013171662 A1 US 2013171662A1
- Authority
- US
- United States
- Prior art keywords
- assay according
- sample
- polypeptide
- cells
- mcm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
Definitions
- the invention relates to a diagnostic/prognostic assay for prostate cancer and including kits used in said assay.
- Cancer is an abnormal disease state in which uncontrolled proliferation of one or more cell populations interferes with normal biological function. The proliferative changes are usually accompanied by other changes in cellular properties, including reversion to a less organised state. Cancer cells are typically referred to as “transformed”. Transformed cells generally display several of the following properties: spherical morphology, expression of foetal antigens, growth-factor independence, lack of contact inhibition, anchorage-independence, and growth to high density. Cancer cells form tumours and are referred to as “primary” or “secondary” tumours. A primary tumour results in cancer cell growth in an organ in which the original transformed cell develops. A secondary tumour results from the escape of a cancer cell from a primary tumour and the establishment of a secondary tumour in another organ.
- prostate cancer can be relatively harmless or extremely aggressive. Some prostate tumours are slow growing and cause few clinical symptoms. Aggressive prostate tumours spread rapidly to the lymph nodes and other organs, especially bone. It is known that the growth of prostate cancer can be inhibited by blocking the supply of male hormones such as testosterone. However, prostate cancers eventually develop and become independent of male sex hormones (i.e. they become androgen-independent prostate cancer cells). These cells are linked with aggressive, malignant prostate cancer. Only two species suffer from prostate cancer; dogs and humans.
- MCM minichromosome maintenance proteins
- AR is a transcription factor and is involved controlling genes involved male sex determination.
- the cloning and sequencing of AR is disclosed in WO89/09791 which describes the expression of AR in prokaryotic and eukaryotic expression systems and its use in the development of monoclonal antibodies.
- PSA is a protease secreted by the cells of the prostate gland.
- the detection of PSA in a blood sample is considered to be indicative of prostate cancer in a subject. This has considerable problems associated with clearly identifying whether a subject requires further investigation. Some subjects that present with high serum levels of PSA are eventually found not to have disease. This causes both psychological stress and unnecessary physical investigation.
- the diagnostic or prognostic assay includes: i) obtaining an isolated cell sample from said biological sample and contacting the isolated cell sample with a binding agent that specifically binds a MCM polypeptide; ii) contacting the isolated cell sample with a further binding agent that specifically binds an androgen receptor polypeptide [AR]; optionally iii) contacting the isolated cell sample with a still further binding agent that specifically binds prostate specific antigen [PSA]; iv) detecting the binding of two or more binding agents; and v) determining the number of cells in said isolated cell sample that positively bind two or more binding agents, wherein the number of positive cells is an indicator of the presence of prostate cancer cells in the biological sample.
- the diagnostic or prognostic assay includes i) obtaining a first isolated biological sample and contacting the sample with a binding agent that specifically binds PSA; optionally ii) detecting the presence of PSA in said sample; iii) obtaining a second biological sample from the subject, preparing an isolated cell sample and contacting said cell sample with first and second binding agents that specifically bind a MCM polypeptide and an androgen receptor polypeptide; iv) detecting the presence of said MCM polypeptide[s] and androgen receptor; and v) determining the number of cells in said isolated cell sample that positively bind both MCM and androgen receptor, wherein the number of positive cells is an indicator of the presence of prostate cancer cells.
- FIG. 1 DAKO colourimetric staining of cultured C4-2b prostate cancer cell line a) with anti-PSA (brown, cytoplasmic), b). with anti-PSA (brown, cytoplasmic) and anti-MCM2 (red, nuclear). Plate a) shows that anti-PSA antibody labels prostate cell cytoplasm (1), and that the nucleus is greatly enlarged (blue haematoxylin stain). Plate b) shows dual staining of cell cytoplasm brown with anti-PSA (1) and nucleus red with anti-MCM2 antibodies (2).
- FIG. 2 Colourimetric single-staining of C4-2b cell line with Vector Stain ImmPRESS reagents. Plates are labelled as follows: —a) DAB staining of nucleus only (1) with N-terminal specific anti-AR antibody, with counter-stained cytoplasm (2); b) non-localised DAB staining of cells with C-terminal specific anti-AR antibody; c) DAB staining of cytoplasm (arrows) with anti-PSA antibody; d) novaRED staining of nucleus (arrows) with anti-MCM2 antibody; and e) novaRED staining of nucleus (arrows) with anti-MCM2 antibody.
- FIG. 3 Colourimetric dual-staining of C4-2b cell line with Vector Stain ImmPRESS reagents. Plate shows DAB-Ni (grey) labelled anti-PSA cytoplasm (1) with novaRED (red) anti-MCM2 antibody labelled nucleus (2).
- FIG. 4 Fluorescent (Alexafluor) staining of cultured C4-2b prostate cancer cell line. Plate a) with anti-PSA antibody (green, cytoplasmic); b) anti-MCM7 (red, nuclear); c) merged, showing distinct separate staining of the two cellular locations and d) merged image using anti-PSA (green, cytoplasmic) and anti-MCM2 (red, nuclear) antibodies showing separate localisation.
- FIG. 5 Fluorescent (Alexafluor) staining of cultured C4-2b prostate cancer cell line. Plate a) with anti-AR antibody (green, nuclear); b) anti-MCM7 (red, nuclear); and c) merged, showing nuclear co-localisation of AR and MCM7 antigens.
- FIG. 6 Dual fluorescent staining of C4-2b prostate cancer cells isolated from a clinical urine sample from patients with confirmed prostatic cancer, with anti-AR (green) and anti-MCM7 (red) antibodies.
- FIG. 7 Removal of injured cells and cellular debris.
- Haemotoxylin stained bladder endothelial cells isolated from urine samples a) without pre-treatment with Immunosolv DeadCert particles and b) after treatment to remove dead or dying cells and other cellular debris.
- FIG. 8 Survival/health of cultured prostatic C4-2b cell nuclei in urine over 4 hours. Clear red nuclear staining indicates that cells are in good condition. Less intense red staining, lack of staining, and increasing cytoplasmic staining indicate that cells are losing viability and would not be clearly identified as prostate cancer cells in patient samples.
- FIG. 9 Dual fluorescent staining of prostate cancer cells isolated from a clinical urine sample from patients with confirmed prostatic cancer, with (a) anti-AR (green) and (b) anti-MCM7 (red) antibodies and (c) Merged image of a double staining with AR and MCM.
- a diagnostic or prognostic method for the detection of prostate cancer cells in a biological sample comprising the steps:
- nuclear receptor polypeptide is Androgen receptor polypeptide (AR).
- said MCM polypeptide is selected from the group consisting of: MCM2, MCM3, MCM4, MCM5, MCM6 or an MCM7 polypeptide.
- said MCM polypeptide is MCM2 and/or MCM7.
- said MCM polypeptide is MCM2.
- said MCM polypeptide is MCM7.
- said MCM polypeptide is MCM2 and MCM7.
- said cell sample is contacted with a binding agent that specifically binds AR and a binding agent that specifically binds PSA.
- said assay detects at least one MCM polypeptide, AR and PSA.
- said assay detects MCM2 and/or MCM7, AR and PSA.
- steps (ii) and (iii) are reversed.
- binding agent is a monoclonal antibody, or active binding fragment thereof.
- the assay provides a diagnostic tool to determine whether a subject has or has not a predisposition to prostate cancer. It also provides a means to determine whether a subject diagnosed and undergoing therapy, for example chemotherapy or radiotherapy, is responding to the treatment or requires and additional or alternative treatment regime. The invention therefore provides a treatment regime for a subject to better manage his disease.
- said biological sample is a sample of isolated bodily fluid, for example urine, semen or seminal fluid.
- Bio samples are typically rapidly processed to reduce degradation of the sample and provide a reliable measure of expression of selected markers.
- samples are chilled [e.g. 4° C.] and processed within at least 1 hour of being obtained.
- said biological sample is a filtered wherein said filtered sample provides said isolated cell sample.
- the filtration device comprises a filter adapted to collect cells of a predetermined size; a fluid pathway arranged to transmit fluid to and from the filter; and a pump which provides a positive pressure which urges the fluid to the filter along the fluid pathway and a negative pressure which draws the fluid from the filter along the fluid pathway.
- a diagnostic or prognostic assay for the determination of prostate cancer in a subject comprising the steps:
- said first biological sample comprises serum.
- said second biological sample is urine or semen.
- said MCM polypeptide is MCM2 and/or MCM7.
- said MCM polypeptide is MCM2.
- said MCM polypeptide is MCM7.
- said detection of binding agents is by fluorescence emission.
- said detection of binding agents is by enzymic means.
- Labels include fluorochromes, phosphor or laser dye with spectrally isolated absorption or emission characteristics. Suitable fluorochromes include fluorescein, rhodamine, phycoerythrin and Texas Red. Suitable chromogenic dyes include diaminobenzidine. Other labels include macromolecular colloidal particles or particulate material such as latex beads that are coloured, magnetic or paramagnetic, and biologically or chemically active agents that can directly or indirectly cause detectable signals to be visually observed, electronically detected or otherwise recorded. These molecules may be enzymes which catalyse reactions that develop or change colours or cause changes in electrical properties, for example.
- They may be molecularly excitable, such that electronic transitions between energy states result in characteristic spectral absorptions or emissions. They may include chemical entities used in conjunction with biosensors. In the examples described below, alkaline phophatase or horseradish peroxidise have been employed.
- kits comprising first second and third binding agents wherein said agents bind a MCM polypeptide, androgen receptor polypeptide and prostate specific antigen polypeptides respectively,
- binding agents are monoclonal antibodies.
- kit further comprises secondary antibodies that bind said first second and third monoclonal antibodies wherein each of said secondary antibodies are provided with fluorescence labels that facilitate the detection of said polypeptides.
- a “binding agent” is an agent of a pair of molecules which have binding specificity for one another.
- the members of a specific binding pair may be naturally derived or wholly or partially synthetically produced.
- One member of the pair of molecules has an area on its surface, which may be a protrusion or cavity, which specifically binds to and is therefore complementary to a particular spatial and polar organisation of the other member of the pair of molecules.
- the members of the pair have the property of binding specifically to each other.
- Examples of types of specific binding agent pairs are antigen-antibody, biotin-avidin, hormone-hormone receptor, receptor-ligand, enzyme-substrate, DNA-DNA (e.g. oligonucleotide).
- the present invention is generally concerned with antigen-antibody type reactions, although it also concerns small molecules which bind to the antigen defined herein.
- antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that specifically binds an antigen, whether natural or partly or wholly synthetically produced.
- the term also covers any polypeptide or protein having a binding domain which is, or is homologous to, an antibody binding domain. These can be derived from natural sources, or they may be partly or wholly synthetically produced.
- antibodies are the immunoglobulin isotypes (e.g., IgG, IgE, IgM, IgD and IgA) and their isotypic subclasses; fragments which comprise an antigen binding domain such as Fab, scFv, Fv, dAb, Fd; and bivalent.
- Antibodies may be polyclonal or monoclonal.
- antibody should be construed as covering any specific binding agent or substance having a binding domain with the required specificity.
- this term covers antibody fragments, derivatives, functional equivalents and homologues of antibodies, humanised antibodies, including any polypeptide comprising an immunoglobulin binding domain, whether natural or wholly or partially synthetic.
- Antibodies which are specific for a target of interest may be obtained using techniques which are standard in the art. Methods of producing antibodies include immunising a mammal (e.g. mouse, rat, rabbit) with the protein or a fragment thereof or a cell or virus which expresses the protein or fragment. Antibodies may be obtained from immunised animals using any of a variety of techniques known in the art, and screened, for example using binding of antibody to antigen of interest.
- An antigen binding domain is the part of an antibody which comprises the area which specifically binds to and is complementary to part or all of an antigen. Where an antigen is large, an antibody may only bind to a particular part of the antigen, which part is termed an epitope.
- An antigen binding domain may be provided by one or more antibody variable domains.
- An antigen binding domain may comprise an antibody light chain variable region (VL) and an antibody heavy chain variable region.
- Specific is generally used to refer to the situation in which one member of a specific binding pair will not show any significant binding to molecules other than its specific binding partner(s), e.g., has less than about 30%, preferably 20%, 10%, or 1% cross-reactivity with any other molecule.
- the specific binding agents of the invention will preferably be, in accordance with the present invention, in “isolated” form. Members will generally be free or substantially free of material with which they are naturally associated such as other polypeptides with which they are found in their natural environment, or the environment in which they are prepared (e.g. cell culture) when such preparation is by recombinant DNA technology practised in vitro or in vivo.
- the specific binding agent of the invention is preferably an antibody, or fragment thereof.
- the specific binding agent may be an antibody, or fragment thereof, having an antigen binding domain specific for PSA or AR.
- the specific binding agent may be an antibody, or fragment thereof, having an antigen binding domain specific for MCM e.g. MCM2 or MCM7.
- the antibody may be a polyclonal antibody, monoclonal antibody, single chain antibody or fragment of any of the foregoing.
- the specific binding agent is a monoclonal antibody.
- Monoclonal antibodies specific for MCM, AR and PSA are known in the art.
- C4-2b cells were cultured in T75 flasks in RPMI media containing 10% FBS and 2% penstrep at 37° C. and 5% CO 2 to 90% confluence. The media was removed by pipetting, and the cells were washed twice with warmed PBS. They were detached from the flask surface by incubating for 2-3 min in 10 ml trypsin solution at 37° C., followed by gentle agitation. The cell suspension was transferred to a 50 ml falcon tube, and the number of cells present determined by counting a sample on a haemocytometer. They were then pelleted by centrifugation and resuspended in warm PBS to 1 ⁇ 10 6 cells/ml.
- Slides were immersed in 50% methanol for 5 min, and rinsed in distilled water before rinsing in TBS (Tris-HCl—buffered saline, DAKO reagent) They were then rinsed with distilled water followed by DAKO wash buffer (S3006), and transferred to the Autostainer (DAKO). Slides were blocked with 200 ⁇ l DAKO dual endogenous enzyme block (product code (K5361) for 5 min, then rinsed twice with TBS. Two hundred ⁇ l primary antibody A0562 rabbit anti-human PSA polyclonal antibody (or control rabbit antibody) was applied at 0.3 ⁇ g/ml and incubated for 30 min. All incubation steps were carried out at room temperature unless otherwise stated.
- TBS Tris-HCl—buffered saline, DAKO reagent
- a heat retrieval step was performed next in order to make the MCM antigen accessible to antibody:—
- Slides were immersed 1 mM EDTA heat retrieval buffer, pH7.8 (DAKO) and micro-waved on full power (800 W, 10 min.). Heat retrieval buffer was replenished, and micro-waving repeated for 10 min. Slides were prepared in this way in batches of 10. Where a smaller number of samples were being prepared, blank slides were included to bring the total number to 10 for consistency of heat treatment. Slides were allowed to cool for 5 min and returned to the auto-stainer.
- slides were rinsed with distilled water and immersed in CuSO 4 solution (10 g CuSO 4 , 17 g NaCl in 2 L water) for 5 min, then rinsed again with water. They were then counterstained with Haematoxylin for 10 s and rinsed with water. Finally slides were immersed in xylene for 5 min, air dried and cover-slipped ready for analysis.
- CuSO 4 solution 10 g CuSO 4 , 17 g NaCl in 2 L water
- Antibodies were diluted from stock solutions in DAKO antibody diluent (S0809 or S2022) to desired concentration. Slides were visualised under white light using a Zeiss AxioSKOP 40 microscope fitted with a Prog Res C14 colour camera. In addition to white light visualisation, the alkaline phosphatase substrate used to label MCM antigens emits fluorescence. This was observed using a Zeiss-Imager M2 with black and white camera Axiocam MRm and a red filter. Images were analysed with Axiovision software ( FIG. 1 ).
- the DAKO rabbit anti-PSA polyclonal antibody A0562 at 0.3 ⁇ g/ml was substituted with one of the following:
- D1.12A3 mouse anti-human MCM2 monoclonal antibody at 1.0 ⁇ g/ml was replaced with one of the following:
- cytoplasmic PSA could be labelled in cultured prostate cells with the D1.12.A3 antibody ( FIG. 1 a ). PSA was also detected with antibodies against ‘epitopes’ 3 and 4, but not with antibodies against ‘epitope’ 1 (not shown). Similarly, antibodies to prostate specific acid phosphatase labelled prostate cell cytoplasm, whereas antibodies to prostate specific G-coupled receptor (PSGR) were not effective. In addition, nuclear antigens mini-chromosome maintenance proteins MCM2 and MCM7, and androgen receptor (AR) provided strong labelling, whereas MCM3 and MCM5 were less effective (not shown). When used in combination in dual staining assays, both PSA and MCM5 ( FIG. 1 b ) and PSA and MCM7 (not shown) could label prostate cells and be individually identified due their different cellular locations.
- Slides were prepared as described in example 1 using a Thinprep T2000 instrument. All labelling and washing steps were performed manually. The slides were first immersed in 50% methanol for 5 min, and 200 ⁇ l DAKO dual endogenous enzyme block (product code (K5361) added for 5 min. The slides were then rinsed 3 times with distilled water and 5 times with DAKO wash buffer (S3006). Ready-to-use ImmPRESS normal horse serum (NHS) at 2.5% was applied to the slides for 20 min to block, followed by 200 ⁇ l DAKO A0562 rabbit anti-human PSA polyclonal antibody (or control rabbit antibody) at 0.3 ⁇ g/ml and incubated for 10 min. All incubation steps were carried out at room temperature unless otherwise stated.
- NHS Ready-to-use ImmPRESS normal horse serum
- Slides were rinsed 5 times with DAKO wash buffer and 200 ⁇ l ImmPRESS Reagent (universal HRP labelled anti-rabbit and anti-mouse) added for 30 min. Slides were rinsed 5 times with DAKO wash buffer and 200 ⁇ l ImmPRESS substrate added for 5 min. Substrate used was any one of Vector VIP (SK-4600, purple), DAB (SK-4100, brown), DAB-Ni (SK-4100, grey/black) or Vector NovaRED (SK-4800, red). Slides were washed 5 times with wash buffer.
- Vector VIP SK-4600, purple
- DAB SK-4100, brown
- DAB-Ni SK-4100, grey/black
- Vector NovaRED SK-4800, red
- a heat retrieval step was performed next in order to make the MCM antigens accessible to antibody:—
- Slides were immersed 1 mM EDTA heat retrieval buffer, pH7.8 (DAKO) and micro-waved on full power (800 W, 10 min.). Heat retrieval buffer was replenished, and micro-waving repeated for 10 min. Slides were prepared in this way in batches of 10. Where a smaller number of samples were being prepared, blank slides were included to bring the total number to 10 for consistency of heat treatment. Slides were allowed to cool for 5 min.
- the 2 nd primary antibody, mouse anti-MCM2 D1.12A3 (MRC, Cambridge, UK) or control mouse antibody was added (200 ⁇ l at 1 ⁇ g/ml) and incubated for 10 min. They were rinsed 5 times with wash buffer, and 200 ⁇ l ImmPRESS Reagent (as above) added for 30 min. After five further rinses with wash buffer, 200 ⁇ l ImmPRESS substrate was added for 5 min. Substrate was any one of the four listed above, but not the same one as used in the earlier step.
- slides were rinsed with distilled water and immersed in CuSO 4 solution (10 g CuSO 4 , 17 g NaCl in 2 L water) for 5 min, then rinsed again with water. They were then counterstained with either Haematoxylin or Methyl green for 10 seconds and rinsed with water. Finally slides were immersed in xylene for 5 min, air dried and cover-slipped ready for analysis.
- CuSO 4 solution 10 g CuSO 4 , 17 g NaCl in 2 L water
- Antibodies were diluted from stock solutions in DAKO antibody diluent (S0809 or S2022) with diluted 2.5% NHS to desired concentration. Slides were visualised under white light using a Zeiss AxioSKOP 40 microscope fitted with a Prog Res C14 colour camera.
- the DAKO rabbit anti-PSA polyclonal antibody A0562 at 0.3 ⁇ g/ml was substituted with the Insight Biotechnology N-20 rabbit anti-androgen receptor N-terminus specific polyclonal antibody (sc816) at 0.3 ⁇ g/ml or anti-androgen receptor C-terminal specific polyclonal antibody (sc815) at 0.3 ⁇ g/ml.
- the D1.12A3 mouse anti-human MCM2 monoclonal antibody at 1.0 ⁇ g/ml was replaced with the Santacruz 141.2 mouse anti-MCM7 monoclonal antibody sc-9966 at 3.0 ⁇ g/ml. Staining was achieved variously using the following ImmPRESS substrates:—DAB (brown), DAB-Ni (grey.black), novaRED (red), or VIP (purple), either singly or in combination, and with or without counterstain.
- DAB-Ni with novaRED and DAB with vecta VIP were found to produce good images ( FIG. 3 ).
- PSA In this assay format, PSA must be used as a prostate cell-specific marker in combination with one or more MCM antigens. Due to it's nuclear localisation, AR is not suitable in this format.
- Prostatic cancer cell line C4-2b was cultured and ‘Thinprep’ slides prepared as detailed in example 1 above.
- Slides were immersed in 50% methanol for 5 min, washed in distilled water for 5 min and rinsed once with DAKO wash buffer. Two hundred microlitres 0.1% Triton X-100 was applied to the slide for 5 min in order to permeabilise the cells. They were then rinsed 3 times with wash buffer and once with water. One hundred microlitres of Image-IT FX signal enhancer (Invitrogen I36933) was applied and incubated at room temperature for 30 min. Slides were rinsed 3 times with wash buffer followed by one rinse with distilled water.
- Urine samples were provided from two patients with confirmed prostatic cancer, and were processed as follows immediately. Samples were centrifuged in 50 ml falcon tubes at 600 g for 5 min to pellet cells, and the supernatant disposed of. The cell pellet was resuspended in a small volume of Cytolyt (Cytyc Corp) by gentle agitation and the tube topped up 30 ml with CytoLyt. The suspension was vortexed for 5 min and re-centrifuged. The cell pellet was resuspended in 100 ⁇ l PreservCyt solution, and transferred to a vial containing 20 ml PreservCyt. The vial was placed in the Thinprep T2000 and slides prepared as described in Example 3 above.
- Cells were labelled with Santacruz 141.2 mouse anti-MCM7 monoclonal antibody sc-9966 at 1.0 ⁇ g/ml and either DAKO rabbit anti-PSA polyclonal antibody A0562 at 0.3 ⁇ g/ml or Insight Biotechnology N-20 rabbit anti-androgen receptor N-terminus specific polyclonal antibody (sc816) at 0.3 ⁇ g/ml ( FIG. 6 ).
- Prostate cells were identified in both samples. They were all of irregular morphology, and exhibited varying degrees of cytoplasmic staining due to the poor condition of the cells after prolonged exposure to urine.
- Urine samples were centrifuged at 600 g for 10 min to pellet cells. Cells were re-suspended in 1 ml PBS. Total cell counts were determined using a haemocytometer. The volume of cell suspension was adjusted such that 100 ⁇ l contained 5 ⁇ 10 6 cells (either by addition of PBS, or re-pelleting and re-suspending in an appropriate volume PBS).
- a stock vial of Immunosolv Dead Cert nanoparticles (Immunosolv Ltd., Edinburgh, UK) was vortexed for 30 s. Twenty five microlitres of nanoparticles were transferred to an Eppendorf tube containing 1 ml PBS. The tube was placed in the provided magnetic separator for 3-5 min, until particles had collected against the magnet. The buffer was removed by pipetting, and the tube removed. Particles were resuspended in 100 ⁇ l PBS by vortexing. One hundred microlitres cells (5 ⁇ 10 6 cells) were added to the particle suspension, and the mixture incubated at 4° C. for 40 min. During this incubation, the magnetic nanoparticles bind to antigens selectively expressed on the surface of any dead or dying cells.
- Prostatic cell line C4-2b was cultured as described in example 1. When culture flasks had reached 80% confluence, cells were harvested by centrifugation, resuspended in PBS (phosphate-buffered saline) and counted. Approximately 2 ⁇ 10 7 cells in 5 ml PBS were added to 25 ml urine provided by healthy donors and stored at 4° C. The samples were removed from the fridge after 1 h, 2 h, 3 h, and 4 h and slides prepared as detailed in example 1 using a Thinprep T2000 instrument.
- PBS phosphate-buffered saline
- the slides were stained using mouse anti-MCM2 D1.12A3 antibody and DAKO anti-mouse alkaline phosphatase reagents as in example 1, and viewed under both white light ( FIG. 8 ).
- the cells showed clear nuclear staining of strong intensity.
- 3 h staining was less clearly nuclear and less intense.
- some cells did not stain positive for MCM.
- the proportion of healthy cells had reduced significantly (data not shown).
- prostate epithelial cells could be captured in the urine of patients presenting with high serum prostate specific antigen (PSA) values.
- PSA prostate specific antigen
- prostate epithelial cell remained intact for up to 4 hours post void (see Example 6).
- a nuclear marker with specific affinity to prostate tissue was selected and investigated. Good definition of prostate cells was achieved using androgen receptor antibodies using both prostate cancer cell lines and in the urines of patients with prostate cancer or those with high serum PSA values.
- Normal urines spiked with an established prostate cancer cell line (C42b) were prepared in the laboratory using urocyte slides on an Hologic T2000 machine. The slides were immersed for 5 minutes in 50% methanol, washed with deionised water and 20 ul 0.2% Triton X-100 added for 5 minutes to permeabilise the cells. A further rinse ⁇ 3 with DAKO buffer and ⁇ 1 with deionised water is followed with 2 drops (100 ul) Image-IT Fx signal enhancer or sufficient volume to cover each coverslip or section and then incubated for 30 minutes at room temperature.
- C42b prostate cancer cell line
- a further rinse ⁇ 3 with buffer and ⁇ 1 with water is followed by incubation with 200 ul of primary antibodies AR (0.3 ug/ml AR-N20 sourced from Santa Cruz catalogue no sc-816) and 1.15 ug/ml MCM (MCM7 sourced from Santa Cruz catalogue no sc9966) in 0.5% milk powder for 60 minutes.
- AR 0.3 ug/ml AR-N20 sourced from Santa Cruz catalogue no sc-816)
- MCM 1.15 ug/ml MCM
- the slides are rinsed ⁇ 3 with buffer and ⁇ 1 with deionised water, and then incubated with the relevant secondary Alexafluor antibodies (alexafluor 488 goat anti-rabbit IgG (H+L; Invitrogen cat no A-11034, and Alexafluor 594 goat anti-mouse IgG1 ( ⁇ 1); Invitrogen cat no A-21125) in the dark for 30 minutes.
- the slides are again rinsed ⁇ 3 with buffer and x 1 with water, prior to the application of 1 drop of Prolong Gold Anti-fade reagent at room temperature followed by coverslipping of all slides.
- the slides are cured by placing the mounted sample on a flat dry surface and incubating at room temperature in the dark for 24 hours. Fluorescence was detected using a fluorescent microscope with different fluorescence filters at 10 seconds ( FIG. 9 ).
- the experiment showed a clear and defined nuclear staining both for Androgen Receptor and Mini Chromosome Maintenance Protein.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0921873.6A GB0921873D0 (en) | 2009-12-15 | 2009-12-15 | Assay |
GB0921873.6 | 2009-12-15 | ||
PCT/GB2010/002274 WO2011073619A1 (fr) | 2009-12-15 | 2010-12-15 | Dosage |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2010/002274 A-371-Of-International WO2011073619A1 (fr) | 2009-12-15 | 2010-12-15 | Dosage |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/489,207 Continuation US10267801B2 (en) | 2009-12-15 | 2014-09-17 | Assay |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130171662A1 true US20130171662A1 (en) | 2013-07-04 |
Family
ID=41667106
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/512,823 Abandoned US20130171662A1 (en) | 2009-12-15 | 2010-12-15 | Assay |
US14/489,207 Active 2032-03-08 US10267801B2 (en) | 2009-12-15 | 2014-09-17 | Assay |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/489,207 Active 2032-03-08 US10267801B2 (en) | 2009-12-15 | 2014-09-17 | Assay |
Country Status (7)
Country | Link |
---|---|
US (2) | US20130171662A1 (fr) |
EP (2) | EP2977762A3 (fr) |
JP (1) | JP2013513812A (fr) |
CN (1) | CN102782497A (fr) |
CA (1) | CA2807870A1 (fr) |
GB (1) | GB0921873D0 (fr) |
WO (1) | WO2011073619A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11391744B2 (en) | 2015-06-08 | 2022-07-19 | Arquer Diagnostic Limited | Methods and kits |
CN107771285A (zh) | 2015-06-08 | 2018-03-06 | 阿奎尔诊断有限公司 | 方法 |
GB201820868D0 (en) * | 2018-12-20 | 2019-02-06 | Arquer Diagnostics Ltd | Detection method |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6303323B1 (en) * | 1997-10-21 | 2001-10-16 | Cancer Research Campaign Technology Limited | Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies |
US6566130B1 (en) * | 2000-01-28 | 2003-05-20 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Androgen-regulated gene expressed in prostate tissue |
US20030105000A1 (en) * | 2000-11-03 | 2003-06-05 | Pero Stephanie C. | Methods and compositions for inhibiting GRB7 |
US20050079576A1 (en) * | 1988-04-15 | 2005-04-14 | French Frank S. | Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions |
US20060211059A1 (en) * | 2005-03-18 | 2006-09-21 | Taneja Samir S | Methods of improving screening, diagnosis and staging of prostate cancer using serum testosterone |
US20110184073A1 (en) * | 2008-06-24 | 2011-07-28 | Cytosystems Limited | Assay |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9704444D0 (en) * | 1997-03-04 | 1997-04-23 | Isis Innovation | Non-invasive prenatal diagnosis |
PE20000121A1 (es) | 1997-10-21 | 2000-02-17 | Cancer Res Campaign Tech | Determinacion de anormalidad en el crecimiento celular |
US6355623B2 (en) * | 1998-09-24 | 2002-03-12 | Hopital-Sainte-Justine | Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage |
WO2005020784A2 (fr) * | 2003-05-23 | 2005-03-10 | Mount Sinai School Of Medicine Of New York University | Signatures d'expression genique de cellules de substitution permettant d'evaluer l'etat physique d'un patient |
US7666595B2 (en) * | 2005-02-25 | 2010-02-23 | The Brigham And Women's Hospital, Inc. | Biomarkers for predicting prostate cancer progression |
CN101239181A (zh) * | 2007-02-08 | 2008-08-13 | 中国科学院上海生命科学研究院 | 一种和癌症有关的组蛋白去甲基化酶及其应用 |
GB0720113D0 (en) * | 2007-10-15 | 2007-11-28 | Cambridge Cancer Diagnostics L | Diagnostic, prognostic and predictive testing for cancer |
GB0800311D0 (en) | 2008-01-09 | 2008-02-20 | Cytosystems Ltd | Apparatus and method for filtering biological material |
-
2009
- 2009-12-15 GB GBGB0921873.6A patent/GB0921873D0/en not_active Ceased
-
2010
- 2010-12-15 CN CN2010800568880A patent/CN102782497A/zh active Pending
- 2010-12-15 US US13/512,823 patent/US20130171662A1/en not_active Abandoned
- 2010-12-15 WO PCT/GB2010/002274 patent/WO2011073619A1/fr active Application Filing
- 2010-12-15 EP EP15185015.3A patent/EP2977762A3/fr not_active Withdrawn
- 2010-12-15 JP JP2012543890A patent/JP2013513812A/ja active Pending
- 2010-12-15 CA CA2807870A patent/CA2807870A1/fr not_active Abandoned
- 2010-12-15 EP EP10801208A patent/EP2513651A1/fr not_active Ceased
-
2014
- 2014-09-17 US US14/489,207 patent/US10267801B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050079576A1 (en) * | 1988-04-15 | 2005-04-14 | French Frank S. | Androgen receptor proteins, recombinant DNA molecules coding for such, and use of such compositions |
US6303323B1 (en) * | 1997-10-21 | 2001-10-16 | Cancer Research Campaign Technology Limited | Detection of dysplastic or neoplastic cells using anti-MCM5 antibodies |
US7056690B2 (en) * | 1997-10-21 | 2006-06-06 | Cancer Research Technology Limited | Detection of dysplastic or neoplastic cells using anti-MCM2 antibodies |
US7459157B2 (en) * | 1997-10-21 | 2008-12-02 | Cancer Research Technology Limited | Detection of dysplastic or neoplastic cells using anti-MCM2 antibodies |
US6566130B1 (en) * | 2000-01-28 | 2003-05-20 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Androgen-regulated gene expressed in prostate tissue |
US20030105000A1 (en) * | 2000-11-03 | 2003-06-05 | Pero Stephanie C. | Methods and compositions for inhibiting GRB7 |
US20060211059A1 (en) * | 2005-03-18 | 2006-09-21 | Taneja Samir S | Methods of improving screening, diagnosis and staging of prostate cancer using serum testosterone |
US20110184073A1 (en) * | 2008-06-24 | 2011-07-28 | Cytosystems Limited | Assay |
Non-Patent Citations (11)
Title |
---|
Boyd (The Basic Science of Oncology, 1992, McGraw-Hill, Inc., p. 379) * |
Burgess et al. (J of Cell Bio. 111:2129-2138, 1990) * |
Coleman et al. (Research in Immunology, 1994; 145(1): 33-36) * |
Diallo et al. (Investigative Urology Feb. 2008, 101:1302-1309) * |
Matsushita et al (FEBS Letters, 1999, Vol. 443, pp. 348-352) * |
Pritzker (Clinical Chemistry, 2002, 48:1147-1150) * |
Rudikoff et al. (PNAS USA, 1982, 79: 1979-1983) * |
Shi et al. (Am. J. Pathol. 173 (6), Dec. 2008) * |
Simon (Lab. Invest. Jan. 2006 86(S1): 161A, Abs. 746) * |
Singh et al. (Glycobiology, 2001, Vol. 11, pp. 587-592) * |
Watkins et al. (Amer. Assoc. Cancer Res. 96th Annual Meeting April 16-20, 2005, Abstract # 3163) * |
Also Published As
Publication number | Publication date |
---|---|
US20150219659A1 (en) | 2015-08-06 |
CN102782497A (zh) | 2012-11-14 |
EP2977762A3 (fr) | 2016-05-04 |
JP2013513812A (ja) | 2013-04-22 |
US10267801B2 (en) | 2019-04-23 |
CA2807870A1 (fr) | 2011-06-23 |
EP2977762A2 (fr) | 2016-01-27 |
EP2513651A1 (fr) | 2012-10-24 |
GB0921873D0 (en) | 2010-01-27 |
WO2011073619A1 (fr) | 2011-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210047697A1 (en) | Method for improved diagnosis of dysplasias | |
EP1934607B1 (fr) | Analyse immunohistochimique multiplexee in situ | |
US9618512B2 (en) | Biomarker for breast cancer | |
US10267801B2 (en) | Assay | |
WO2004077021A2 (fr) | Evaluation normalisee de l'efficacite therapeutique fondee sur des marqueurs biologiques cellulaires | |
US10145850B2 (en) | Assay | |
US9213029B2 (en) | Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients | |
ES2793485T3 (es) | Ensayos de receptores esteroideos para la detección de células tumorales | |
CN112236677A (zh) | 直接免疫组织化学和免疫细胞化学方法 | |
CN110221072B (zh) | 检测H3K9甲基化和E-cadherin表达量试剂在制备肝癌预后评估试剂盒的应用 | |
US20070134742A1 (en) | Diagnostic reagent for uterine adenocarcinoma and method of detecting adenocarcinoma cells | |
WO2007103538A2 (fr) | Procedes de marquage d'anticorps multiples et utilisations desdits procedes | |
EP3124974A1 (fr) | Procédé de normalisation de tests immunologiques et kits destines a effectuer de tels tests |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CYTOSYSTEMS LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LASKEY, RONALD A.;REEL/FRAME:028760/0962 Effective date: 20120720 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |